The thread shows Endo-205 remains in very early stages with a Phase 1 trial not finishing until 2027 and no sequence publicly available yet. Some users compare it to earlier peptides that appeared in limited circles long before wider release, while others argue its narrower patient base makes quick grey-market spread unlikely. Participants agree ongoing treatment potential exists but differ on how soon broader access might occur.
What this discussion establishesWhether Endo-205 will reach grey-market sources on a timeline similar to Reta or Elora, or remain niche and scarce for longer.
Still openAny concrete timeline or source for wider availability.
Nothing here is advice.
My girlfriend has endometriosis and I'm trying to locate this peptide. Has anyone come across it anywhere?
I've looked everywhere but can't locate that sequence, seeing only announcements along with promises instead. The health funding details indicate the recent round closed out, and the initial trial phase concludes March 31, 2027. Still, possessing one real study trumps empty assurances. Has anybody found references to a study they might mention?
I came across a news piece this morning regarding approval for human trials. This made me really hopeful for my spouse since her endo affects her so severely. Let me know if anyone locates a provider. I haven't succeeded in doing so.
I acquired one of them way prior to when it was released to everyone, and it's still not out there. Not sure about the status of the second one's regulatory steps, though only a single seller carries it so far, and it doesn't seem like the cost will drop in the near future. It would be good if the third option showed up earlier to allow more folks to try it out.
I doubt we'll see that development before long. It's unfortunate how many more folks deal with excess weight versus endometriosis. The bigger demand pulls focus toward slimming agents as the main influence. Someday maybe, but probably as a specialized option that's not widely obtainable.
Peptides exist that target various conditions outside of just shedding pounds, and development on this one is progressing currently. Given how it impacts around 190 million females, the potential returns seem substantial. Also, similar to GLP1s, it likely won't eliminate the issue permanently but will require continuous use, which appeals to major pharmaceutical companies.
I apologize for the lack of clarity earlier. I'm aware peptides serve purposes beyond weight reduction alone. My response addressed a discussion mentioning grey market options for those two items, which shaped the comparison I made. Pharma companies will probably pursue further development if profit potential exists. Grey market access seems less probable though. Most current options in that space target broad goals like longevity, weight reduction, recovery, or skin health. Few focus on one narrow condition. Broader applications beyond the initial intent, similar to one created for a medical condition in patients yet discovered to have wider applications, would raise the odds of grey market appearance. This remains my personal view drawn from patterns I notice now, and I'm only addressing grey availability here. I'd welcome being incorrect.
If you have tried it, this topic is still open. Sign in to reply — it takes a minute.